-
1 Comment
Aridis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 55.6.
Aridis Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow fell by 253.0% to $-5M since the same quarter in the previous year.
Based on the above factors, Aridis Pharmaceuticals, Inc gets an overall score of 3/5.
| Exchange | PINK |
|---|---|
| CurrencyCode | USD |
| ISIN | US0403341045 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4K |
|---|---|
| PE Ratio | None |
| Target Price | 2 |
| Beta | -81.23 |
| Dividend Yield | None |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ARDS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
